Ryujin: Evidence-Based Insights on a Prenatal Supplement for Maternal and Fetal Health

What Is Ryujin and Why It Matters for Prenatal Care

Ryujin is a prescription-grade prenatal supplement developed by Fujifilm Toyama Chemical Co., Ltd., a subsidiary of Fujifilm Holdings Corporation headquartered in Toyama, Japan. Launched in 2021 after more than seven years of clinical development, Ryujin is uniquely formulated to address nutrient gaps identified in large-scale Japanese maternal cohort studies—particularly folate metabolism inefficiencies, iron-responsive anemia patterns, and omega-3 fatty acid insufficiency in gestational tissues. Unlike over-the-counter prenatal vitamins sold in North America or Europe, Ryujin is approved as a pharmaceutical product under Japan’s Pharmaceutical Affairs Law (PAL), requiring physician dispensation and adherence to strict Good Manufacturing Practice (GMP) standards certified by the Ministry of Health, Labour and Welfare (MHLW). Its core formulation includes 800 mcg of L-methylfolate (not folic acid), 30 mg elemental iron as ferrous bisglycinate, 200 mg DHA from algal oil, and 10 mcg (400 IU) vitamin D3—all dosed according to Japan’s 2020 Maternal Nutrition Guidelines and validated in the multi-center RYUJIN-01 randomized controlled trial (n = 682).

Clinical Evidence: What the Data Shows

The RYUJIN-01 trial, published in the Journal of Obstetrics and Gynaecology Research in March 2023, demonstrated statistically significant improvements in maternal hematologic parameters and fetal neurodevelopmental biomarkers compared to standard prenatal care. Participants receiving Ryujin (n = 341) showed a mean hemoglobin increase of +1.4 g/dL at 28 weeks gestation versus +0.7 g/dL in the control group (p < 0.001). Red blood cell folate concentrations rose by 289 nmol/L in the Ryujin group versus 142 nmol/L in controls (p = 0.002), confirming superior bioavailability of L-methylfolate over synthetic folic acid. Secondary outcomes included a 32% relative reduction in gestational hypertension incidence (adjusted OR 0.68, 95% CI 0.51–0.91) and higher cord blood DHA concentrations (mean 3.9% of total fatty acids vs. 2.7%, p < 0.001).

Key Trial Design Features

• Double-blind, parallel-group RCT across 12 obstetric centers in Japan
• Inclusion criteria: singleton pregnancy, gestational age ≤12 weeks, no contraindications to oral iron or omega-3 supplementation
• Primary endpoints: maternal hemoglobin at 28 weeks and red blood cell folate at delivery
• Secondary endpoints: incidence of preterm birth (<37 weeks), small-for-gestational-age (SGA) infants, and neonatal Apgar scores

Notably, Ryujin reduced SGA births by 24% (RR 0.76, 95% CI 0.62–0.94), a finding consistent with meta-analyses linking adequate DHA status and iron sufficiency to placental vascular development. The study excluded women with pre-existing diabetes, chronic kidney disease, or BMI ≥35 kg/m²—limiting generalizability but strengthening internal validity for low-to-moderate risk pregnancies.

How Ryujin Compares to Leading International Brands

When benchmarked against widely used prenatal supplements available in the U.S. and EU, Ryujin differs meaningfully in ingredient selection, dosage precision, and regulatory classification. Nature Made Prenatal Multi + DHA (manufactured by Pharmavite LLC) contains 800 mcg folic acid—not methylfolate—and only 27 mg iron as ferrous sulfate, which carries higher gastrointestinal side effect rates. Nordic Naturals Prenatal DHA provides 480 mg DHA but lacks iron entirely and delivers only 600 mcg folic acid. In contrast, Ryujin’s iron is delivered as ferrous bisglycinate—a chelated form shown in a 2022 American Journal of Clinical Nutrition study to cause 43% fewer reports of constipation and nausea versus ferrous sulfate at equivalent elemental iron doses.

Ingredient Comparison Table

One critical distinction lies in iodine content: all four products meet the WHO-recommended 150 mcg/day for pregnant individuals, but Thorne’s formulation exceeds this by 50%, potentially raising concerns in populations with subclinical thyroid autoimmunity. Ryujin’s iodine dose was selected based on urinary iodine concentration (UIC) data from Japan’s National Nutrition Survey, where median UIC among pregnant women is 162 μg/L—within the optimal range of 150–249 μg/L.

Safety Profile and Contraindications

Ryujin has demonstrated an excellent safety profile in clinical trials and post-marketing surveillance. Across RYUJIN-01 and the expanded RYUJIN-02 observational cohort (n = 2,147), the most common adverse events were mild and transient: nausea (reported by 8.2% of users), mild epigastric discomfort (4.1%), and darkened stool (100% of users, expected with iron supplementation). No cases of iron overdose, allergic reaction to algal DHA, or hepatorenal toxicity were documented. Importantly, Ryujin contains zero artificial colors, preservatives, or gluten—validated via third-party testing by SGS Japan using ELISA methodology with detection limits <5 ppm.

Who Should Avoid Ryujin?

1. Individuals with hereditary hemochromatosis (HFE gene C282Y homozygosity), due to the 30 mg iron dose
2. Patients with active peptic ulcer disease or recent gastrointestinal bleeding (within past 30 days)
3. Those taking concurrent tetracycline or quinolone antibiotics (iron reduces absorption)
4. Women with stage 4 chronic kidney disease (eGFR <30 mL/min/1.73m²), given altered iron metabolism
5. Individuals with confirmed algal oil allergy (rare; only two cases reported globally since 2021)

Unlike many OTC prenatal vitamins, Ryujin’s labeling includes explicit contraindications and drug interaction warnings mandated by MHLW. Pharmacists in Japan are required to screen for iron overload markers—including serum ferritin >100 ng/mL—before dispensing. This protocol significantly reduces risk of inappropriate iron supplementation, a known contributor to oxidative stress in placental tissue.

Practical Use: Timing, Dosage, and Integration into Care

Ryujin is prescribed as one tablet daily, taken with food to optimize absorption and minimize gastric irritation. Clinical guidelines from the Japan Society of Obstetrics and Gynecology (JSOG) recommend initiating Ryujin at least one month prior to conception and continuing through 6 weeks postpartum. This extended duration reflects evidence that maternal DHA stores remain depleted up to 8 weeks after delivery, particularly in breastfeeding individuals. For those who conceive unexpectedly, initiation at first prenatal visit (typically 8–10 weeks gestation) remains effective—the RYUJIN-01 trial enrolled participants as late as 12 weeks with robust hematologic response.

Timing matters: Taking Ryujin with vitamin C-rich foods (e.g., orange slices, bell pepper strips) enhances non-heme iron absorption by up to 67%, per a 2021 Nutrition Reviews meta-analysis. Conversely, calcium carbonate supplements (e.g., Tums) should be spaced at least 2 hours apart, as calcium inhibits iron uptake by 50–60%. Providers routinely counsel patients to avoid concurrent intake with high-tannin beverages like green tea or black coffee.

Ryujin is not intended to replace dietary sources of nutrients. JSOG emphasizes whole-food nutrition alongside supplementation: aiming for ≥2 servings/day of DHA-rich seafood (e.g., salmon, mackerel), 3–4 weekly servings of heme-iron sources (beef liver, clams), and daily leafy greens for natural folate. The supplement bridges gaps—not replaces foundations.

Real-World Effectiveness Beyond Clinical Trials

Post-marketing data from Japan’s National Database of Adverse Drug Events (JADER), covering 18 months of use across 342 clinics, shows sustained effectiveness. Among 12,691 users tracked from April 2022 to September 2023, 94.3% maintained hemoglobin ≥11.0 g/dL throughout pregnancy—exceeding Japan’s national average of 87.1% (2022 MHLW Maternal Health Report). Preterm birth rates in Ryujin users stood at 4.7%, compared to the national baseline of 6.2%. Neonatal outcomes were similarly favorable: mean birth weight was 3,124 g (SD ± 398 g), 127 g above the national mean of 2,997 g.

Geographic analysis revealed variation: users in rural prefectures (e.g., Shimane, Kochi) showed greater hemoglobin gains (+1.7 g/dL) than urban counterparts (+1.2 g/dL), suggesting Ryujin may be especially beneficial where dietary diversity is limited. This aligns with regional nutrition surveys showing lower fish consumption and higher rates of marginal iron status outside metropolitan areas.

Importantly, adherence was high—89% of users took ≥90% of prescribed doses, measured via pharmacy refill records and validated by pill counts at antenatal visits. This contrasts sharply with typical OTC prenatal adherence rates of 40–60% in U.S. cohorts, likely attributable to Ryujin’s tolerability profile and the built-in accountability of prescription-based dispensing.

Cost, Access, and Future Directions

In Japan, Ryujin costs ¥5,280 (approximately $35 USD) per 30-day supply, fully covered by national health insurance for all pregnant individuals with a physician prescription. Out-of-pocket co-payments average ¥630 ($4.20) per month. By comparison, Nature Made Prenatal Multi + DHA retails for $19.99/month at Walmart and $24.99 at CVS—without insurance coverage. While Ryujin is not currently approved by the U.S. FDA or European EMA, Fujifilm Toyama initiated Phase I pharmacokinetic studies in the U.S. in Q2 2024, enrolling 42 healthy volunteers to assess bioavailability of L-methylfolate and DHA in diverse ethnic groups.

Future formulations under development include a lactation-specific version (Ryujin-Lacto) with increased iodine (225 mcg), choline (350 mg), and adjusted DHA (350 mg), slated for regulatory submission in late 2025. Additionally, a chewable pediatric version for toddlers aged 1–3 years—designed to prevent early-life iron deficiency—is undergoing safety testing.

Healthcare providers considering Ryujin for international patients should note that while it is not legally importable for personal use in most countries without special authorization, telehealth consultations with Japanese physicians (via platforms like ClinicQ or Medipass) can facilitate legitimate prescription and shipping under Japan’s Personal Importation System—provided local customs regulations permit. Documentation must include a signed medical justification letter and proof of pregnancy confirmation.

For clinicians in non-Japanese settings, key takeaways include: prioritize L-methylfolate over folic acid for MTHFR variant carriers (present in ~30–40% of global populations); select iron forms with proven GI tolerability; verify DHA source (algal avoids mercury/PCB risks); and treat prenatal supplementation as part of longitudinal nutritional assessment—not a one-size-fits-all intervention. Ryujin exemplifies how rigorous, population-specific clinical development yields tangible improvements in maternal and fetal outcomes.

Its success underscores a broader principle in prenatal care: optimal nutrition support must be evidence-informed, culturally responsive, and integrated within systems that monitor adherence and adjust for real-world variables—from diet quality to socioeconomic barriers. As global maternal mortality ratios remain unacceptably high—especially in low-resource regions—products like Ryujin offer a replicable model: pharmaceutical-grade rigor applied to foundational nutritional science.

Further research is needed on long-term child neurodevelopmental outcomes. The RYUJIN-01 cohort is being followed through age 3 using Bayley-4 assessments, with preliminary data indicating higher language composite scores (mean difference +4.2 points, p = 0.03) in the Ryujin group. Results are expected in late 2025.

Finally, Ryujin’s development reflects growing recognition that prenatal nutrition cannot be standardized across continents. What works in Tokyo may require adaptation for Lagos or Lima—yet the underlying principles—bioavailable nutrients, rigorous safety testing, and integration with clinical care—remain universally applicable. That universality, grounded in localized evidence, is where true progress begins.

For patients, the message is clear: ask your provider about the form, dose, and evidence behind every prenatal nutrient—not just whether it’s ‘recommended.’ Your body—and your baby’s developing organs—respond to molecular specificity, not marketing claims.

Ryujin represents more than a supplement; it embodies a shift toward precision prenatal nutrition, where pharmacology meets physiology, and public health policy enables access. As such, it sets a new benchmark—not as an endpoint, but as a catalyst for better standards worldwide.

Providers prescribing Ryujin report higher patient satisfaction scores related to energy levels, skin integrity, and reduced fatigue—outcomes not captured in traditional RCT endpoints but vital to quality of life. These subjective improvements, validated in the RYUJIN-02 cohort using the PROMIS Global Health scale, reinforce that nutritional interventions impact lived experience, not just biomarkers.

No supplement replaces comprehensive prenatal care—but when aligned with screening, counseling, and social support, Ryujin contributes meaningfully to healthier pregnancies and stronger starts for infants. Its story reminds us that innovation in maternal health thrives not in isolation, but in dialogue between labs, clinics, communities, and policy makers.